Entropy Technologies LP Trims Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Entropy Technologies LP lowered its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 51.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,125 shares of the medical research company’s stock after selling 5,408 shares during the quarter. Entropy Technologies LP’s holdings in Charles River Laboratories International were worth $1,009,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the company. Tortoise Investment Management LLC lifted its stake in shares of Charles River Laboratories International by 77.0% during the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock valued at $27,000 after buying an additional 57 shares in the last quarter. Wolff Wiese Magana LLC bought a new position in shares of Charles River Laboratories International in the third quarter worth about $32,000. Assetmark Inc. grew its position in shares of Charles River Laboratories International by 1,153.3% during the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after purchasing an additional 173 shares in the last quarter. Headlands Technologies LLC bought a new stake in Charles River Laboratories International during the 1st quarter valued at approximately $41,000. Finally, Whittier Trust Co. of Nevada Inc. lifted its holdings in Charles River Laboratories International by 219.3% in the 2nd quarter. Whittier Trust Co. of Nevada Inc. now owns 281 shares of the medical research company’s stock worth $58,000 after purchasing an additional 193 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the company’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the transaction, the director now owns 12,386 shares of the company’s stock, valued at $2,676,862.32. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 1.30% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Redburn Atlantic started coverage on shares of Charles River Laboratories International in a report on Monday, October 14th. They set a “sell” rating and a $151.00 price objective for the company. Barclays reduced their price target on shares of Charles River Laboratories International from $230.00 to $210.00 and set an “equal weight” rating on the stock in a report on Thursday, August 8th. Citigroup downgraded shares of Charles River Laboratories International from a “neutral” rating to a “sell” rating and dropped their price objective for the company from $215.00 to $175.00 in a report on Tuesday, October 1st. TD Cowen lifted their target price on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a report on Monday. Finally, StockNews.com lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $217.54.

Charles River Laboratories International Trading Down 4.4 %

Shares of CRL opened at $206.54 on Thursday. The company’s fifty day simple moving average is $195.14 and its 200-day simple moving average is $207.90. The company has a market cap of $10.56 billion, a P/E ratio of 25.85, a P/E/G ratio of 5.57 and a beta of 1.38. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. Charles River Laboratories International, Inc. has a twelve month low of $174.92 and a twelve month high of $275.00.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $975.99 million. During the same period in the prior year, the company posted $2.72 EPS. The firm’s revenue for the quarter was down 1.6% on a year-over-year basis. As a group, analysts expect that Charles River Laboratories International, Inc. will post 10.18 EPS for the current year.

Charles River Laboratories International declared that its Board of Directors has initiated a stock repurchase program on Wednesday, August 7th that permits the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization permits the medical research company to buy up to 9.6% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s leadership believes its shares are undervalued.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).